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Chemokines (chemotactic cytokines) comprise a large family of
proteins that recruit and activate leukocytes, giving chemokines a
major role in both immune response and inflammation-related
diseases. The poxvirus-encoded viral CC chemokine inhibitor (vCCI)
binds to many CC chemokines with high affinity, acting as a potent
inhibitor of chemokine action. We have used heteronuclear mul-
tidimensional NMR to determine the structure of an orthopoxvirus
vCCI in complex with a human CC chemokine, MIP-1 (macrophage
inflammatory protein 1). vCCI binds to the chemokine with 1:1
stoichiometry, forming a complex of 311 aa. vCCI uses residues
from its -sheet II to interact with a surface of MIP-1 that includes
residues adjacent to its N terminus, as well as residues in the 20s
region and the 40s loop. This structure reveals the strategy used
by vCCI to tightly bind numerous chemokines while retaining
selectivity for the CC chemokine subfamily.
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Chemokines play critical roles in the immune system, causingchemotaxis of a variety of cells to sites of infection and
inflammation, as well as mediating cell homing and immune system
development (1). To date, 50 chemokines have been identified,
and these small proteins (7–14 kDa) are believed to function by
binding with endothelial or matrix glycosaminoglycans (GAGs) to
form a concentration gradient that is then sensed by high-affinity,
seven-transmembrane domain, G protein-coupled chemokine re-
ceptors on the surface of immune cells, leading to activation and
chemotaxis. The chemokine system is critical for host defense in
healthy individuals and can lead to diseases such as asthma,
arthritis, and atherosclerosis in the case of malfunction, often due
to inappropriate inflammation and subsequent tissue damage (2).
There are four subfamilies of chemokines, CC, CXC, C, and CX3C,
named for the position of conserved N-terminal cysteine residues.
Members of the same subfamily often have overlapping receptor-
binding and cell activation abilities, whereas different subfamilies
tend to function on different cell subsets (1).
Structures of chemokines from different subfamilies have been
elucidated by NMR and x-ray crystallography (3–6). Despite the
differences in amino acid composition and functionalities, most
chemokines share a remarkably conserved tertiary structure, with
an extended N terminus followed by three -strands in a Greek key
arrangement and aC-terminal-helix. The solution structure of the
humanCC chemokineMIP-1 (macrophage inflammatory protein
1) revealed a homodimer (7), and, subsequently, the dimer
dissociation constant was determined to be 0.73 M (8). Dimer-
ization of other chemokines has been observed under in vitro
conditions, and the ability to dimerize is necessary for some
chemokines to function in vivo (9).
Given the importance of understanding the interaction between
chemokines and their binding partners, considerable effort has
been made to study the binding of chemokines to both GAGs and
chemokine receptors by a range of techniques (10, 11). However,
structure determinations of chemokines in complex with any bio-
logical molecule are rare and include only a chemokine:GAG
complex (12), a chemokine:protein complex (13), and a chemoki-
ne:receptor fragment peptide complex (14).
All known pox and herpes viruses encode proteins that interfere
with the host chemokine network, likely as part of a strategy to
manipulate and subvert the immune system (15). Such virally
encoded proteins include chemokine mimics, chemokine receptor
analogs, and a group of secreted, soluble chemokine-binding pro-
teins (CKBPs) that exhibit little similarity to any mammalian
protein (16). CKBPs competitively bind to chemokines and disrupt
chemokine interactions with the host cell surface receptors or
GAGs. Although someCKBPs interact with a very broad spectrum
of chemokines across several chemokine subfamilies, the viral CC
chemokine inhibitor (vCCI) proteins (previously called T135 kDa,
also classified as type II CKBPs) produced by leporipoxviruses and
orthopoxviruses bind selectively to members of the CC subfamily
(16, 17). vCCI proteins have been shown to be potent inhibitors of
chemokine action in vitro (17) and effective anti-inflammatory
agents in vivo (18). Sequence alignment of vCCI proteins from five
orthopoxvirus members [rabbitpox, cowpox, vaccinia-Lister, vac-
cinia-Copenhagen, and variola poxvirus (the causative agent of
human smallpox)] shows at least 80% identity (Fig. 1), with some
pairwise comparisons showing as much as 99% sequence identity,
indicating that they have essentially identical structures and very
likely share characteristics of chemokine binding. The x-ray crystal
structure of unliganded cowpox vCCI by Carfi et al. (19) revealed
a unique -sandwich structure with no topological resemblance to
any mammalian receptors. Although -sheet I in this sandwich has
two extended loops that effectively shield it from solvent, -sheet
II is exposed to solvent and was hypothesized by these researchers
to include a chemokine-binding surface.
Here, we report the solution structure of a complex between
rabbitpox-encoded vCCI and a nonaggregating variant of the
humanCC chemokineMIP-1. The structure reveals that the vCCI
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and MIP-1 form a complex in a 1:1 stoichiometry and that vCCI
occludes the regions in the chemokine that are important for
chemokine homodimerization, receptor binding, and GAG inter-
action. The structure also defines key interactions that form the
basis for the affinity and selectivity of vCCI toward certain CC
chemokines.
Results
Solution Structure Determination of the vCCI:MIP-1 Complex. Al-
though vCCI is a highly soluble and well folded protein at physi-
ological pH, many CC chemokines prefer acidic conditions in vitro
and aggregate near pH 7 at concentrations required for NMR
experiments. Therefore, a nonaggregating human MIP-1 variant
in which three positively charged amino acid residues in the
so-called 40s loop (45KRSK48) were replaced byAla was chosen for
the current study. The resulting protein, MIP-1-45AASA48, has
been found to be soluble at neutral pH while maintaining most
spectral and functional characteristics of the WT protein with the
exception of loss of GAG-binding ability (20). (For simplicity, when
discussing the complex, MIP-1-45AASA48 will hereafter be re-
ferred to as MIP-1.)
Because of the relatively large size of vCCI (26 kDa), side-chain
deuteration was used to reduce linewidths for better spectral
resolution. Resonance assignments of both components in the
complex were carried out with a series of standard 2D and 3D
experiments by using 15N-labeled, 13C,15N-labeled, and 2H,13C,15N-
labeled proteins. Essentially complete backbone and side-chain 1H,
13C, and 15N chemical-shift assignments for bound MIP-1 and
1HN, 13C, 13C, 13C, 15N chemical-shift assignments for bound and
free vCCI were obtained and are reported elsewhere (21, 22).
Deviation of chemical shift from random coil values allowed
predictions of secondary structure for both protein components in
the complex (23) and suggests that, in the complex, both proteins
preserve the secondary structure elements that are present in their
unliganded forms (7, 19).
Upon titration of 15N-labeled vCCI with 14NMIP-1, two sets of
vCCI peaks in the 15N heteronuclear single quantum correlation
spectra (HSQC) were evident when 1 equivalent of MIP-1
subunits was added, indicating slow exchange between two confor-
mations on anNMRtimescale. The spectrum resolved into only one
peak per vCCI 15N-1H resonance after addition of 1 full equivalent
ofMIP-1 subunits, with additional amounts ofMIP-1 causing no
further spectral change, consistent with a 1:1 ratio of proteins in the
complex (Fig. 2A). 15N relaxation experiments were carried out on
the complex by using both 15N vCCI:14NMIP-1 and 14N vCCI:15N
MIP-1. The rotational correlation timewas calculated to be 13.2
0.7 ns for 15N vCCI in complex and 13.1  0.6 ns for 15N MIP-1
in complex (data not shown). These values are both consistent with
a molecular mass of 34 kDa, confirming a complex with 1:1
stoichiometry.
Fig. 2. Observation of vCCI:MIP-1 interaction. (A) Overlay of the 15N heteronuclear single quantum correlation (HSQC) spectra of free (black) and liganded
(red) vCCI. (B) Chemical shift perturbation mapping of vCCI upon addition of MIP-1. Residues with weighted average HN and N chemical shift perturbation1
standard deviation (SD) from the mean value are shown in red. Residues that are missing from the HSQC because of chemical exchange line broadening are shown
in yellow. (C) Overlay of the 15N HSQC spectra of free (black) and liganded (red) MIP-1.
Fig. 1. Sequence alignment of five members of the orthopox
vCCI family. Alignments were made by using ClustalW. RPV,
rabbitpox virus; VAR, variola virus; VVL, vaccinia virus Lister
strain; VVC, vaccinia virus Copenhagen strain; CPV, cowpox
virus. Conserved residues are highlighted in yellow.
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Protein–protein complex formation is often accompanied by
changes in 15N-1H chemical shifts of residues in regions that are
affected by the binding interaction. Chemical-shift perturbation
mapping reveals the likely binding sites on both proteins. For vCCI,
the vast majority of chemical shift perturbations upon association
with MIP-1 occur on -sheet II and the nearby loops, with a few
additional changes directly across the-sandwich in-sheet I, likely
due to propagation of changes from -sheet II (Fig. 2B). The
MIP-1 spectra show significant change upon binding vCCI (Fig.
2C), particularly in the regions associated with the chemokine
dimer interface, indicating alteration in this part of the protein
caused by the breaking of the MIP-1 homodimer and binding
with vCCI.
Residual dipolar coupling (RDC) constants were measured in
the presence of alignment medium to obtain structural restraints as
well as the relative orientation of the two binding partners (see the
supporting information, which is published on the PNAS web site).
NOESY data were also obtained by using complexes composed of
proteins with various isotopic labeling schemes to facilitate resolu-
tion of the spectra. Three-dimensional 15N-NOESY of
1HN,15N,13C-labeled vCCI in complex with unlabeled MIP-1 and
3D 13C-NOESYand 15N-NOESYof 13C,15N-labeledMIP-1 in the
presence of unlabeled vCCI were used for verification of chemical-
shift assignments and to obtain intramolecular NOE constraints.
These data also confirm that both proteins in the complex retain the
same overall tertiary fold and secondary structures as in the
unbound form.
Direct structural information of the binding interface was ob-
tained by using a 4D 15N,13C-edited NOESY experiment (24) that
was measured on a 2H,1HN,15N vCCI:13C,14N MIP-1 sample (see
the supporting information). Because of the differential isotopic
labeling of the proteins in the complex, this experiment shows
resonances only for intermolecular contacts, providing distance
information between the amide protons of vCCI and any nearby
side-chain and backbone HC protons of MIP-1. A total of 32
distinct intermolecular NOE restraints were obtained from this
spectrum and from the 3DNOESY experiments mentioned above.
The structure of the complex was calculated to be consistent with
a total of 917 constraints, including RDC, dihedral angle, andNOE
distance restraints (Table 1). The final ensemble of 15 structures
shows a 0.78-Å rmsd for backbone atoms. The atomic coordinates
for the ensemble of 15 NMR structures (Protein Data Bank ID
code 2FIN) and the averaged energy-minimized structure (PDB ID
code 2FFK) have been deposited in the Protein Data Bank.
Description of the vCCI:MIP-1 Structure. The vCCI:MIP-1 com-
plex is formed by one monomer of vCCI interacting with one
monomer of MIP-1 (Fig. 3). Each component of the complex is
largely similar in conformation to the proteins in their unliganded
forms. MIP-1 spans the entire width of vCCI, making contacts
across the vCCI -sheet II starting with MIP-1 residue 8, through
the 20s region, and including the 40s loop and the third -strand,
constituting a protein:protein interface with a 2,200-Å2 buried
solvent-accessible surface area (1.4-Å probe). The extended
MIP-1 N-terminal fragment from Pro-8 to Ser-14 is positioned
almost parallel to the vCCI -strand 8, making numerous contacts
with residues from Ser-182 to Thr-187. The residue Phe-13 of
MIP-1 is proximal to a hydrophobic cluster formed by highly
conserved vCCI residues, including Val-185 and Tyr-217. The
strand ofMIP-1 continues across the -sheet II face of vCCI, with
theArg-18 side chain protruding toward the vCCI residues Asp-141
and Glu-143, consistent with involvement in electrostatic interac-
tions. The 20s region and 40s loop of MIP-1 fit into a binding
surface formed by vCCI strands 2 and 3 and the loop connecting
these two strands. The third -strand ofMIP-1 is oriented roughly
orthogonal to the vCCI -strands and interacts with residues from
vCCI -strands 4, 7, and 8.
Binding of MIP-1 to vCCI by Using ELISA.Quantitative ELISAs were
carried out to determine the relative affinity for vCCI of WT
MIP-1 and the variant used in the present structure determina-
tion. These studies reveal an EC50 forWTMIP-1 of 0.66 0.4 nM
and an EC50 for MIP-1-45AASA48 of 0.64  0.6 nM (see the
supporting information).
Discussion
vCCIs comprise a group of poxvirus-encoded proteins with highly
conserved sequence and unique structural topology. These proteins
tightly bind and inhibit the action of CC chemokines but have low
or no affinity for chemokines of other subfamilies, making them
potent and specific anti-inflammatory agents with demonstrated
effectiveness in vivo (18, 25). An extensive binding study with
vaccinia vCCI using 80 chemokines from several organisms
revealed 26 CC chemokines that bind with high affinity, including
13 human chemokines, such asMCP-1 (monocyte chemoattractant
protein 1), MIP-1, MIP-1, and RANTES (26). To probe the
chemokine residues that are important in vCCI binding, two
previous studies using vCCI and variants of human CC chemokine
MCP-1 suggested that the MCP-1 monomeric subunit binds vCCI
through an interface that is partially overlapping with the site that
Table 1. NMR and refinement statistics for the
vCCI:MIP-1 complex





Sequential (i  j  1) 264
Nonsequential (i  j  1) 222
Protein–protein intermolecular 32








Violations (mean  SD)
Distance constraints, Å 0.020  0.003
Dihedral angle constraints, ° 0.54  0.04
Max. distance constraint violation, Å 0.217  0.068
Max. dihedral angle violation, ° 3.83  0.53
Deviations from idealized geometry
Bond lengths, Å 0.00457  0.00014
Bond angles, ° 0.587  0.015
Improper angles, ° 0.427  0.026
Average pairwise rmsd, Å
vCCI
Heavy 1.64  0.09
Backbone 0.42  0.08
MIP-1
Heavy 1.61  0.18
Backbone 0.38  0.05
Complex
Heavy 1.78  0.12
Backbone 0.78  0.25
*Fifteen structures from the final ensemble were included in the analysis.
Residues 1–7 and 56–76 in vCCI were excluded from pairwise rmsd cal-
culation. The force constants used for the structure calculation are as fol-
lows: 1,000 kcalmol1Å2 for bond lengths, 500 kcalmol1rad2 for
angles and improper torsions, 4 kcalmol1Å4 for quartic van der Waals
repulsions, 80 kcalmol1Å2 for experimental interproton distances, 200
kcalmol1rad2 for the TALOS-predicted torsion angle restraints, and
0.1–0.5 kcalmol1Hz2 for residual dipolar coupling.







MCP-1 uses to bind its natural receptors, with residues Tyr-13,
Arg-18, andArg-24 found to be particularly important (27, 28). The
present work displays the structural underpinning of the high
affinity between poxvirus vCCI and CC chemokines.
In the vCCI:MIP-1 structure, vCCI makes no contact with the
first seven chemokine residues, which are involved in receptor
activation (8). However, the highly conserved vCCI residues Ser-
182 to Thr-187 make extensive contacts with the MIP-1 residues
Pro-8 to Ser-14. This region of MIP-1, and in particular Phe-13,
has been shown to be critical to the chemokine both for receptor
binding and for dimer formation (8), providing a clear rationale for
the inhibitory capability of vCCI. The positioning of the MIP-1
N-terminal region allows its Phe-13 to make close contact with
hydrophobic vCCI residues, from 8 at the edge of -sheet II and
10 from the opposing -sheet I (Fig. 4A). These residues are at
the edge of a large hydrophobic network between the two sheets of
the vCCI -sandwich so that Phe-13 of MIP-1 makes a ‘‘cap’’ on
the network. An amino acid with a shorter or a polar side chain
would not be able to make these contacts and would therefore lack
this component of binding affinity. Indeed, detailed mutagenesis
studies of the CC chemokine MCP-1 show an 10-fold reduction
in affinity when analogous residue Tyr-13 is replaced by Ala (27,
28). In all human chemokines that bind tightly to vCCI, this position
is an aromatic or a large hydrophobic amino acid (26), again
demonstrating the importance of this residue in both the function
and inhibition of CC chemokines.
Another important interaction in the complex involves a posi-
tively charged Arg-18 of MIP-1. Our structure reveals that this
residue is in close proximity to the conserved, negatively charged
vCCI residues Asp-141 and Glu-143. In 12 of the final ensemble of
15 structures, the MIP-1 Arg-18 guanidino group is within 3.9 Å
or less of the  carboxyl group of Asp-141 of vCCI so that Asp-141
is well positioned for electrostatic interaction (Fig. 3). Although this
interaction is not shielded from water, mutagenesis experiments on
MCP-1 indicate its significance, showing a 20-fold reduction in
affinity when Arg-18 is substituted with Ala (27, 28). Additionally,
sequence analysis of human chemokines that bind vCCI shows a
nearly universal positive charge at this position (Fig. 5).
A particularly intriguing interaction occurs between the chemo-
kine 20s region and the large, flexible vCCI loop that connects the
2 and 3 strands. Among the CC chemokines having high affinity
with vCCI, some have a large hydrophobic residue at this position
(such as MIP-1 with Phe-24), whereas others have a positively
charged residue (such as MCP-1 with Arg-24). Both types of
residues at this position are apparently allowed, which raises the
question of whether this amino acid takes part in the binding
interaction, and, if so, how two completely different amino acid
types are tolerated here. The answer to this question is quite
important from a structural standpoint, because it provides insight
into the ability of vCCI to maintain selectivity yet bind such a large
number of chemokines. The structure of the vCCI:MIP-1 complex
shows that the 24th position in MIP-1 faces the loop in vCCI
between the 2 and 3 strands (Fig. 4B). In all orthopox vCCI
proteins, this loop region is highly acidic, with50%of the residues
being Asp or Glu. 15N relaxation studies reveal that this region is
quite flexible regardless of the presence of the boundMIP-1 (data
not shown). The arrangement of negative charges and the confor-
Fig. 3. Solution structure of the vCCI:MIP-1 complex. Superposition of 15
NMR structures is shown, with the vCCI backbone colored red and selected side
chains colored pink. The MIP-1 backbone is blue, and selected side chains are
shown in green.
Fig. 4. Detailed views of the VCCI:MIP–1 interaction. (A) MIP-1 Phe-13
(green) and the surrounding hydrophobic residues (yellow) from vCCI. (B)
View of the 20s region and the 40s loop of MIP-1 (green) in proximity to vCCI
acidic residues (red). In the present structure, MIP-1 residues 45, 46, and 48
are changed to Ala to enhance solubility.
Fig. 5. Sequence alignment of human CC chemokines with high affinity to
vCCI. Conserved cysteine residues are highlighted in yellow. Positions high-
lighted with red indicate residues that likely confer high-affinity binding to
vCCI. The numbering is according to the MIP-1 sequence.
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mational plasticity in this region of vCCI allow favorable interac-
tions to positively charged residues in the chemokine and have
minimal hindrance to large hydrophobic residues. A negatively
charged chemokine residue at this position would be expected to be
disfavored by the highly acidic loop, which explains the observation
that an Arg-24-Glu MCP-1 mutant has no detectable binding to
vCCI by surface plasmon resonance (28). Regarding vCCI inter-
actions with those chemokines having a neutral rather than a basic
residue at this 24th position, the high flexibility of the acidic vCCI
loop region surrounding MIP-1 residue Phe-24 makes it difficult
to pinpoint specific contacts, so it is possible that Phe-24 itself does
not contribute favorably to binding vCCI. However, the chemokine
40s loop is close in space to the 24th position and often contains
a basic amino acid(s) at the turn, such as Lys-45 in WT MIP-1
(Figs. 4B and 5), so productive electrostatic-binding interactions are
expected with the acidic flexible loop of vCCI. This interaction
compensates for the absence of basic residues at the 24th position.
In MCP-1 studies, the loss of Arg-24 by mutation to Ala was not
compensated by a nearby positive charge (WT MCP-1 has Ile and
Val at the 45th and 46th positions, respectively, using MIP-1
numbering), causing a10-fold drop in affinity. An analysis of the
sequences of the human chemokines that bind tightly to vCCI shows
that they all have at least one positive charge in the 24th or the 45th
position (with one chemokine having a positive charge at position
46 instead; Fig. 5).
The MIP-1 variant used here has mutations K45AR46A
K48A, which, overall, lead to an affinity for vCCI approximately the
same as that of the WT chemokine, as determined by ELISA (see
the supporting information). Although neutralization of the Lys at
position 45would be expected to decrease the affinity of themutant
by the above argument, replacing the large basic Lys residue with
Ala at position 48 apparently compensates for this change. In the
current structure, the 48th position is approached closely by the side
chains of vCCI Tyr-80 and Arg-89, so substitution of Lys-48 by Ala
in MIP-1 could alleviate steric crowding and poor electrostatic
effects of the WT protein. In support of this, the analogous
mutation in MCP-1 Lys-49–Ala actually showed an increase in
affinity for vCCI (27, 28).
In the present structure, the GAG-binding region of MIP-1,
composed of residues from the 40s loop as well as Arg-18 (11, 29),
interacts with vCCI. Therefore, we expect vCCI to interfere with
GAG binding by MIP-1 and by chemokines that share a similar
GAG-binding site. Inhibition of chemokine GAG binding is a
strategy that has been demonstrated for other viral proteins and
may disrupt the chemokine concentration gradient that is necessary
for directed chemotaxis of leukocytes (30, 31).
The only other reported protein:protein complex involving a
chemokine is the x-ray crystal structure of the -herpesvirus protein
M3 in complex with a monomeric variant of the CC chemokine
MCP-1 (13). M3 is a large protein that is able to bind chemokines
from all four chemokine subfamilies. Although both M3 and vCCI
share some properties of chemokine binding, their strategies are
distinct. Most obvious, the M3:MCP-1 binding interface is unre-
lated to the vCCI:MIP-1 interface reported here. M3 primarily
uses the loops at the edge of two different domains to contact each
MCP-1 subunit (binding in a 2:2 complex); in contrast, vCCI uses
much of its -sheet II to contact MIP-1 and forms a 1:1 complex.
M3 makes close contacts to residues involved in the receptor-
binding surface of MCP-1, such as Tyr-13 and Arg-18, but only
peripherally contacts the residues of the 40s loop of the chemokine,
which appear to be largely solvent-exposed.
Overall, then, the ability of vCCI to inhibit many CC chemokines
hinges on several key interactions, ranging from occlusion of the
receptor-binding residues to a likely blockade of the chemokine
GAG-binding site. Sequence analysis of human chemokines having
high affinity to vCCI exhibits a conserved pattern (Fig. 5): Hydro-
phobic residue 13, as well as positively charged residue 18, is a
near-absolute requirement. Residue 24 and members of the 40s
loop are close in space, and there is a requirement for at least one
positive charge in the 2445 position; the lack of a positive charge
at one of these sites (e.g., 24) is always compensated by at least one
positive charge at the other (e.g., 45, or, in one case, 46). CC
chemokines that have high affinity to vCCI (such as MIP-1 and
MCP-1) show adherence to these principles, whereas chemokines
having lower affinity to vCCI (such as TARCCCL17) do not. CXC
chemokines almost universally lack several elements of this pattern,
particularly at positions 18 and 24, and so have low or no affinity to
vCCI. In summary, this work elucidates the structure of a
vCCI:chemokine complex and reveals a general strategy used
by vCCI for selective chemokine binding, which could provide a
guideline for future therapeutic design.
Methods
Sample Preparation. The gene encoding the human MIP-1 non-
aggregating mutant K45AR46AK48A (MIP-145AASA48) was
subcloned into a modified pET-32 XaLIC vector as described in
ref. 8. The resulting plasmid was then transformed into BL21-
(DE3) Escherichia coli cells. Unlabeled, 15N-labeled, 13C,14N-
labeled, and 13C,15N-labeledMIP-1 45AASA48 were produced and
purified by following the protocol described in ref. 8.
The gene encoding rabbit poxvirus vCCIwas cloned into pPIC9K
plasmid and then transformed into Pichia pastoris strain SMD1168
(Invitrogen, Carlsbad, CA). Unlabeled, 15N-labeled, 2H,15N-
labeled, and 2H,13C,15N-labeled protein samples were prepared by
growing cells in buffered minimal glucose medium for initial
biomass accumulation and then shifting cells into bufferedminimal
methanol media with 15N (or 14N for unlabeled samples) ammo-
nium sulfate and 13C (or 12C for unlabeled samples)methanol as the
sole nitrogen and carbon sources for induction (32). For deuterated
samples, the medium was prepared with 95% (final concentration)
D2O. The recombinant protein was purified by anion exchange
chromatography followed by size-exclusion chromatography. To
fully exchange amide protons in the deuterated samples, the vCCI
protein was partially unfolded in H2O buffer with 2 M urea,
followed by a 10-fold quick dilution. After allowing the protein to
fully refold, the protein was exchanged into the final NMR buffer.
The final NMR samples contained 0.5–2.0 mM protein(s) (with
concentration determined in monomeric subunits) in 93%
H2O7%D2Ocontaining 100mMNaCl, 20mMsodiumphosphate
(pH 7.0), 0.1 mM DSS, 0.01% sodium azide, and Complete
Protease Inhibitor (Roche Applied Science, Indianapolis, IN).
NMR Spectroscopy. Spectra were recorded at 37°C on Inova 600,
750, and 800 spectrometers (Varian, Palo Alto, CA). NMR data
were processed by using NMRPipe (33). Bound and free
2H,15N,13C-labeled vCCI were used to obtain backbone and C
assignments (34). Bound 13C,15N-labeled MIP-1 45AASA48 was
used to obtain backbone and side-chain assignments. The observed
chemical shift change (obs) for each backbone amide between
bound and free vCCI was measured as the weighted average of the
proton and nitrogen chemical shift changes by using the equation
obs  [(2HN 	 2N25)2]1/2 (35).
3D 15N-NOESY of 2H,15N,13C-labeled vCCI in complex with
unlabeled MIP-1 and 3D 13C-NOESY and 15N-NOESY of
13C,15N-labeled MIP-1 in the presence of unlabeled vCCI were
carried out as described in ref. 36. To detect intermolecular
restraints, a 4D 13C,15N-edited NOESY (24) was recorded on a
complex of 2H,1HN,15N vCCI with 13C,14N MIP-1. Details of
NMR experiments can be found in the supporting information.
15N T1, T2, and 15N-HN NOE values were measured for both
components of the complex (37). Data were excluded from the
correlation time calculation if the corresponding 15N-HN NOE
was 0.65 or if either T1 or T2 differed from the average value
by 1 SD.







RDC.Polyacrylamide gel (4.8%) was used to align the sample. The
samples were prepared by using the apparatus developed by
Chou et al. (38) and purchased from New Era Enterprise
(Vineland, NJ), following a similar protocol to that described by
Mohana-Borges et al. (39). The RDCs of resolved 1H-15N were
measured by using the IPAP scheme (40) for both components
of the complex (41).
Structure Calculation. Torsion angles and were derived from the
TALOSdatabase (42). Structureswere calculated by usingDynamo
(45). ForMIP-1-45AASA48, the high-resolutionNMR structure of
the WT MIP-1 (PDB ID code 1HUM) was used to prepare a
starting input for the calculation. For rabbitpox vCCI, the sequence
was first aligned with the unliganded cowpox vCCI (PDB ID code
1CQ3) and then threaded by Modeller 8v1 (43) to obtain a starting
set of coordinates for calculation. As the first step, separate
structural refinement of each protein was carried out. The high
temperature in the annealing steps was kept at 500 K so that large
changes in conformation were not likely unless heavy violation of
the NMR data occurred. Ten structures were chosen from a
calculation of 50 structures based on adherence to experimental
restraints and low overall energy. These 10 structures were then
used to obtain an averaged energy-minimized structure, which was
further refined withRDC restraints. The resulting refined structure
of vCCI showed 0.25-Åbackbone rmsd from the 1CQ3 structure for
213 aligned residues, showing the same overall fold. Similarly, the
resulting refined structure of MIP-1 45AASA48 showed 0.16-Å
backbone rmsd from amonomeric unit of theWT structure. These
two initially refined protein structures were then used as inputs to
calculate the complex structures. At this stage, the backbone atoms
of each protein were constrained within 0.2 Å of the input coor-
dinates without penalty, and the side chains were allowed to move
freely to satisfy other restraints. The final ensemble of 15 structures
was selected from an ensemble of 100 structures based on lowest
energy and no violation of NOE restraints by 0.4 Å or dihedral
restraints by5°. PROCHECK analysis shows that, for the ensem-
ble of 15 structures, 70.2% of the residues are in the most favored
region, 26.5%are in the additionally allowed region, 2.7%are in the
generously allowed region, and 0.6% are in the disallowed region.
ELISAs. Ninety six-well OptiPlate-HB plates (PerkinElmer, Welle-
sley, MA) were coated with 100l of 65 nM vCCI overnight at 4°C.
The plate was then washed with 0.1% Tween 20 in PBS (PBS-
Tween), and excess binding sites were blocked with 300 l of
blocking buffer (0.5% BSA in PBS-Tween) for 2 h at room
temperature with constant agitation. The wells were again washed
with PBS-Tween, after which serial dilutions of chemokines in
blocking buffer were added and incubated for 2 h at room tem-
perature with constant agitation. After washing, 100 l of 400
ngml polyclonal antibody to human MIP-1 (R & D Systems,
Minneapolis, MN) was added, incubated for 1 h, and then washed.
One hundred microliters of 400 ngml mouse anti-goat IgG con-
jugated with horseradish peroxidase (Pierce, Rockford, IL) was
then incubated for 1 h and washed. One hundred microliters of
AmershamECL reagent (GEHealthcare, Buckinghamshire, U.K.)
was added and incubated for 10 min, followed by detection with an
Orion microplate luminometer (Berthold, Oak Ridge, TN). The
EC50 was determined by using three separate experiments, each
performed in triplicate.
Figure Preparation. Structure figures were prepared by using UCSF
Chimera (44).
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